Stress, hostility, and disease parameters of benign prostatic hyperplasia

Psychosomatic Medicine

Volumn 67, Issue 3, 2005, Pages 476-482

  Ullrich, Philip M ^a,e   Lutgendorf, Susan K ^b   Leserman, Jane ^d   Turesky, Derek G ^b   Kreder, Karl J ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b University of Iowa   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Benign prostatic hyperplasia; Hostility; Prostate; Stress

Indexed keywords

DOXAZOSIN; FINASTERIDE; PLACEBO; TESTOSTERONE;

ADRENERGIC SYSTEM; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HOSTILITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PSYCHOLOGICAL ASPECT; RESIDUAL URINE; SELF REPORT; STRESS; SYMPTOMATOLOGY; URINE VOLUME;

AGED; HOSTILITY; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROSTATIC HYPERPLASIA; STRESS, PSYCHOLOGICAL; URINARY RETENTION; URINATION DISORDERS; URODYNAMICS;

EID: 19444378784     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.psy.0000161208.82242.f8     Document Type: Article

References (66)

1. Walsh PC. Benign prostatic hyperplasia. In: Walsh PC, Gittes RF, Perlmutter AD, eds. Campbell's Urology, 6th ed. Philadelphia: WB Saunders, 1992:1009.
2. Hollander JB, Diokno AC. Prostatism: benign prostatic hypeplasia. Urol Clin North Am 1996;23:75-86.
3. Berry SJ, Coffey DS, Walsh PC. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-85.
4. Lee CL, Kozlowski JM, Grayhack JT. Etiology of benign prostate hyperplasia. Urol Clin North Am 1995;22:237-46.
5. Lepor H. Alpha blockage for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1995;22:375-86.
6. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1995;22:247-61.
7. Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med 1980;68:745-52.
8. McConnell JD. Benign prostatic hyperplasia: hormonal treatment. Urol Clin North Am 1995;22:387-400.
9. McKeehan WL, Adams PS, Rosser MP. Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoids, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 1984;44:1998-2002.
10. Fitzparrick J. Clinical perspective on apoptosis in the management of the BPH patient. Prostate 2000;S9:47-50.
11. Nakaki DT, Nakayama M, Yamamoto S, Kato R. Alpha-1 adrenergic stimulation and beta-2 adrenergic inhibition of DNA synthesis in vascular smooth muscle cells. Mol Pharmacol 1990;37:30-6.
12. Hieble JP, Caine M, Zalaznik E. In vitro characterization of the alpha-adrenoreceptors in human prostate. Eur J Pharmacol 1985;107:111-7.
13. Debruyne FMJ. Alpha blockers: are all created equal? Urology 2000; 56(s5A):20-2.
14. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. JAMA 1992;267:1244-52.
15. Sapolsky RM. Neuroendocrinology of the stress response. In Becker JB, Breedlove SM, Crews D, eds. Behavioral Endocrinology. Cambridge, MA: MIT Press, 1992:287-324.
16. Mills PJ, Ziegler MG, Patterson T, Dimsdale JE, Hauger R, Irwin M, Grant I. Plasma catecholamine and lymphocyte beta-sub-2-adrenergic receptor alterations in elderly Alzheimer caregivers under stress. Psychosom Med 1997;59:251-6.
17. Mazur A, Michalek J. Marriage, divorce, and male testosterone. Social Forces 1998;77:315-30.
18. Dell'Erba G, Pancheri P, Intreccialagli B. Hormonal assessment and workload correlates in air traffic controllers at the end of night shift: the stress perspective. New Trends in Experimental & Clinical Psychiatry 1988;4:197-212.
19. Aakvaag A, Bentdal O, Quigstad K, Walstad P, Rohnnongen H, Fonnum F. Testosterone and testosterone-binding globulin (TeBG) in young men during prolonged stress. Int J Androl 1978;1:22-31.
20. Kreuz LE, Rose RM, Jennings JR. Suppression of plasma testosterone levels and psychologicall stress. Arch Gen Psychiatry 1972;26:479-82.
21. Thompson WM, Dabbs JM, Frady RL. Changes in salivary testosterone levels during a 90-day shock incarceration program. Criminal Justice and Behavior 1990;17:246-52.
22. Nilsson PM, Moller L, Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. J Intern Med 1995;237:479-86.
23. Spielberger CD, Johnson EH, Russell SF, Crane RJ, Jacobs GA, Worden TJ. The experience and expression of anger: Construction and validation of an anger expression scale. In: Chesney MA, Rosenman RH, eds. Anger and Hostility in Cardiovascular and Behavioral Disorders. New York: McGraw-Hill, 1985:5-30.
24. Hardy JD, Smith TW. Cynical hostility and vulnerability to disease: social support, life stress, and physiological response to conflict. Health Psychol 1988;7:447-59.
25. Christensen, AJ, Smith TW. Cynical hostility and cardiovascular reactivity during self-disclosure. Psychosom Med 1993;55:193-202.
26. Suarez EC, Williams RB. Situational determinants of cardiovascular and emotional reactivity in high and low hostile men. Psychosom Med 1989;51:404-18.
27. Suarez EC, Kuhn CM, Schanberg SM, Williams R, Zimmerman EA. Neuroendocrine, cardiovascular, and emotional responses of hostile men: the role of interpersonal challenge. Psychosom Med 1998;60:78-88.
28. Stone AA, Mezzacappa ES, Donatone BA, Gonder M. Psychosocial stress and social support are associated with prostate-specific antigen levels in men: results from a community screening program. Health Psychol 1999;18:482-6.
29. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
30. Sarason IG, Johnson JH, Siegel JM. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychol 1978;46:932-46.
31. Russo J, Vitaliano PP. Life events as correlates of burden in spouse caregivers of persons with Alzheimer's disease. Exp Aging Res 1995; 21:273-94.
32. Kessler RC, Wethington E. The reliability of life events reports in a community survey. Psychol Med 1991;21:723-38.
33. Leserman J, Murphy C, Evans DL. Stress Rating Manual for the Coping in Health and Illness Project (CHIP). Chapel Hill: University of North Carolina, 2000.
34. Evans DL, Leserman J, Perkins DO, Stern RA, Murphy C, Zheng B, Gettes D, Longmate JA, Silva SG, van der Horst CM, Hall CD, Folds JD, Golden RN, Petitto JM. Severe life stress as a predictor of early disease progression in HIV infection. Am J Psychiatry 1997;154:630-4.
35. Buss AH, Perry M. The aggression questionnaire. J Pers Soc Psychol 1992;63:452-9.
36. Combes GM, Millard RJ. The accuracy of portable ultrasound scanning in measurement of residual urine volume. J Urol 1994;152:2083-5.
37. Christensen MM, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin North Am 1990;17:509-16.
38. Eckhardt MD, van Venrooij GE, Boon TA. Symptoms, prostate volume, and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia. Urology 2001;58:966-71.
39. Sech S, Montoya J, Girman CJ, Rhodes T, Roehrborn CG. Interexaminer reliability of transrectal ultrasound for estimating prostate size. J Urol 2001;166:125-9.
40. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT, for the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148: 1549-64.
41. Jaccard J, Turrisi R, Wan CK. Interaction Effects in Multiple Regression. Newbury Park, CA: Sage, 1990.
42. Seidman SN, Roose SP. The male hypothalamic-pituitary-gonadal axis: Pathogenic and therapeutic implications in psychiatry. Psychiatr Ann 2000;30:102-12.
43. Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatry 1998;155:1310-8.
44. Lee C. Physiology of castration-induced regression in rat prostate. In: Murphy G, Sandberg A, Karr J, eds. The Prostatic Cell: Structure and Function. New York: Alan Liss, 1981.
45. Staack A, Kassis AP, Olshen A, Wang Y, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate 2003;54:212-9.
46. Gatenbeck L, Johansson B, Stromberg L. Blood perfusion of the male genital organs-an experimental study in the rat. Urol Res 1987;15: 291-5.
47. Gatenbeck L, Johansson B, Stromberg L, Svensson M. Genital blood flow in male rats subjected to stress stimuli. Urol Res 1987;15:297-301.
48. Eyres HM. Nervous retention of urine. BMJ 1912;1:484-5.
49. Berlin RM, Carvell MC, Noori OS, Tan L. Psychogenic urinary retention in a man. Psychosomatics 1980;21:611, 706.
50. Chapman AH. Psychogenic urinary retention in women. Psychosom Med 1959;21:119-22.
51. Norden CW, Friedman EA. Psychogenic urinary retention: report of 2 cases. N Engl J Med 1961;264:1096-7.
52. Straub LR, Ripley HS, Wolf S. Disturbance of bladder function associated with emotional states. JAMA 1949;141:1139-43.
53. Williams GE, Johnson AM. Recurrent urinary retention due to emotional factors: report of a case. Psychosom Med 1956;18:77-80.
54. Abramovici I, Assael M. Psychogenic retention of urine. Psychiatr Clin 1981;14:196-204.
55. Allen TD. Psychogenic urinary retention. South Med J 1972;65:302-4.
56. DeLancey JO. Structural aspects of the extrinsic continence mechanism. Obstet Gynecol 1988;72:296-301.
57. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, Candib D. Behavioral vs. drug treatment for urge urinary incontinence in older women. JAMA 1998;280:1995-2000.
58. Mayo ME. Detrusor hyperreflexia: the effect of posture and pelvic floor activity. J Urol 1978;119:635-8.
59. Reitz A, Schmid DM, Curt A, Knapp PA, Jensen K, Schurch B. Electrophysiological assessment of sensations arising from the bladder: are there objective criteria for subjective impressions? J Urol 2002;169: 190-4.
60. Marshall I, Burt RP, Chapple CR. Noradrenaline contractions of human prostate mediated by alpha 1A-adrenoreceptor in the human prostate. Br J Urol 1995;74:585-9.
61. Caine M, Raz S, Ziegler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule, and bladder neck. Br J Urol 1975;27: 193-200.
62. Kihara K, Sato K, Oshima H. Involvement of the adrenal medulla in ejaculatory reactions in the dog. Int J Androl 1997;20:104-11.
63. 1 blockade in prostatic hyperplasia. Urology 1988;32(suppl):21-4.
64. Suls J, Wan CK. The relationship between trait hostility and cardiovascular reactivity: a quantitative review and analysis. Psychophysiology 1993;30:615-26.
65. Burns JW. Anger management style and hostility: predicting symptom-specific physiological reactivity among chronic low back pain patients. J Behav Med 1997;20:505-21.
66. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol 1946;6:117-230.